(4bR,8R,8aS,9aS,11aS,11bR)-7-(cyclopropylmethyl)-1-hydroxy-11-phenyl-5,6,7,8,9a,11b-hexahydro-8a,11a-ethano-4,8-methano-9,12,14-trioxa-7,11-diazabenzo[a]benzo[4,5]cycloocta[1,2,3-gh]pentalen-10(11H)-one | 1391951-47-5

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - Oxamorphinans
• 英文名称: (4bR,8R,8aS,9aS,11aS,11bR)-7-(cyclopropylmethyl)-1-hydroxy-11-phenyl-5,6,7,8,9a,11b-hexahydro-8a,11a-ethano-4,8-methano-9,12,14-trioxa-7,11-diazabenzo[a]benzo[4,5]cycloocta[1,2,3-gh]pentalen-10(11H)-one
• 英文别名: (1S,11R,15R,16R,17S,19S)-12-(cyclopropylmethyl)-6-hydroxy-22-phenyl-2,4,18-trioxa-12,22-diazaheptacyclo[15.4.2.15,9.01,16.011,19.015,19.015,24]tetracosa-5,7,9(24)-trien-23-one
• CAS: 1391951-47-5
• 化学式: C₂₉H₃₀N₂O₅
• 分子量: 486.568
• InChiKey: MWNDHOWKMXFYLQ-HRPGWMCCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  36
• 可旋转键数：
  3
• 环数：
  9.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  71.5
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  (4bR,8R,8aS,9aS,11aS,11bR)-7-(cyclopropylmethyl)-1-methoxy-11-phenyl-5,6,7,8,9a,11b-hexahydro-8a,11a-ethano-4,8-methano-9,12,14-trioxa-7,11-diazabenzo[a]benzo[4,5]cycloocta[1,2,3-gh]pentalen-10(11H)-one 在 三溴化硼 作用下， 以 二氯甲烷 为溶剂， 反应 0.5h， 以89%的产率得到(4bR,8R,8aS,9aS,11aS,11bR)-7-(cyclopropylmethyl)-1-hydroxy-11-phenyl-5,6,7,8,9a,11b-hexahydro-8a,11a-ethano-4,8-methano-9,12,14-trioxa-7,11-diazabenzo[a]benzo[4,5]cycloocta[1,2,3-gh]pentalen-10(11H)-one
  参考文献：
  名称：

  Novel Delta Opioid Receptor Agonists with Oxazatricyclodecane Structure

  摘要：

  We synthesized compounds 4a,c-f,h,i containing the oxazatricyclodecane structure from a novel rearrangement reaction product 2a. All the prepared compounds 4a,c-f,h,i exhibited full agonistic activities for the delta opioid receptor (DOR). Among them, the N-methyl derivative 4c was highly selective, and the most effective DOR agonist in functional assays. Subcutaneous administration of 4c produced dose-dependent and NTI (selective DOR antagonist)-reversible antinociception lacking any convulsive behaviors in the mice acetic acid writhing tests. The N-methyl derivative 4c is expected to be a promising lead compound for selective DOR agonists with a novel chemotype.

  DOI：

  10.1021/ml400491k